AstraZeneca's Q3 Attributable Profit, Revenue Grow

03:24 AM EDT, 10/30/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) logged $3.12 billion in profit attributable to owners of the parent for the third quarter, compared with $2.53 billion a year ago. EPS moved to $2 from $1.62, a Friday filing showed. For the three months ended Sept. 30, total revenue was $16.21 billion versus $15.19 billion, the London- and Stockholm-listed drugmaker added. Analysts polled by FactSet were expecting $12.03 billion in sales, $3.03 billion in net income, and $1.90 in EPS. For full-year 2026, AstraZeneca maintained its forecast of mid-to-high single-digit percentage growth in total revenue and a low double-digit percentage increase in core EPS.